Latest HealthCap News
Aug 9, 2021
Other backers of the €30m fundraising included Sweden’s HealthCap, funds managed by US-based Tekla Capital Management, and Berlin-based EarlyBird Venture Capital. That money was earmarked by Priothera for advancing clinical development of mocravimod, including generating additional randomised clinical trial data in high-risk acute myeloid leukaemia patients. Mocravimod has already been extensively tested in multiple immunologic indications, according to Priothera. It has shown survival benefit in an early clinical study evaluating acute myeloid leukaemia and acute lymphocytic leukaemia patients undergoing so-called hematopoietic stem cell transplantation. Drug giant Novartis originally acquired the worldwide rights to mocravimod from Kyorin in 2006. But the drug never went beyond phase 2 clinical trials. Dr Gros, Mr Suire and Dr Patel were all working at Novartis when the drug company held the rights to mocravimod. Dr Gros was the managing director of Novartis’s venture capital fund for more than 10 years, while Dr Patel was in charge of the company’s autoimmunity and transplantation research. Mr Suire had a number of financial roles at Novartis. Most Watched
2 Team Members
HealthCap has 2 team members, including current Founding Partner, Peder Fredrikson.